Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 46, Issue 7, 2005, Pages 1051-1055

  Rashid, Kamran ^a   Ng, Richard ^a   Mastan, Alina ^a   Sager, Dianne ^a   Hirschman, Richard ^a  

^a CABRINI MEDICAL CENTER   (United States)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; Immunosuppression; Skin carcinomas

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RESISTANCE; CASE REPORT; CAUSE OF DEATH; CHRONIC DRUG ADMINISTRATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE EXACERBATION; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LYMPHOCYTOPENIA; MALE; METASTASIS; PRIORITY JOURNAL; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SKIN NEOPLASMS; TREATMENT OUTCOME; VIDARABINE;

EID: 22144483123     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500096989     Document Type: Article

References (26)

1. Huang P, Chubb S, Plunkett W. Termination of DYN synthesis by 9-B-D-arabinofuranosyl-2-fluroadenine. J Biol Chem 1990;265:16-17.
2. Yang S-W, Huang P, Plunkett W, Becker FF, Chan YH. Dual mode of inhibition of purified DNA ligase I from human cells by 9-B-D-arabinofuranosyl-2-fluroadenine troposphere. J Biol Chem 1992;267:23-45.
3. Puccio CA, Mittelman A, Lichtman SM, Sliver RT, Budman DR, Ahmed T, Feldman EJ, Coleman M, Arnold PM, Arlin ZA, Chun HG. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncology 1991;9:1562-1569.
4. Carson DA, Carrera CJ, Wasson DB, Yamanaka H. Programmed cell death and adenine nucleotide metabolism in human lymphocytes. Adv Enzyme Regul 1987;27:395-404.
5. Carson DA, Seto S, Wasson DB, Carrera CJ. DNA strand breaks, NAD metabolism and programmed cell death. Exp Cell Res 1986;164:273-281.
6. Carson DA, Wasson DB, Beutler E. Antileukemic immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Sci USA 1984;81:2232-2236.
7. Mengubas K, Riordan FA, Bravery CA, Lewis J, Owens DL, Mehta AB, Hoffbrand AV, Wickremasinghe RG. Ceramide induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism. Oncogene 1999;18: 2499-2506.
8. Dighiero G. Adverse and beneficial immunological effects of purine nucleoside analogues. Hematology Cell Ther 1996;38:S75-S81.
9. Donofrio J, Coleman MS, Hutton JJ, et al. Overproduction of adenosine deoxynucleosides and deoxynucleotides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest 1978;62:884-887.
10. Wilson PK, Szabados E, Muigan SP, Christopherson RI. Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T and B cell lines. Int Biochem Cell Biol 1998;30:833-842.
11. Frank DA, Mahajan S & Ritz J. Fludarabine induced immunosuppression is associated with inhibition of STAT 1 signaling. Nature Med 1997;5: 444-447.
12. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E. Long-term follow up of patients with CLL receiving fludarabine regimes as initial therapy. Blood 1998;92:1165-1171.
13. Kolb HJ, Socie G, Duell Th, Van Lint MT, Tichelli A, Apperley JF, Nekolla E, Ljungman, P, Jacobsen PN, van Weel M, Weiss M, Prentice HG. Malignant neoplasm in long term survivors of bone marrow transplantation. Ann Int Med 1999;131:738-744.
14. Davidovitz Y, Ballin A, Meytes D. Squamous cell carcinoma of the skin acceleration of development and growth complicating chronic lymphocytic leukemia. Acta Haemtol 1997;98:4446.
15. Sager D, Fulman M, Prasd C, Rivera Y, Hirschman R. Squamous cell carcinoma of the skin: Acceleration of development and growth complicating chronic lymhpocytic leukemia treatment with fludarabine (abstract). Proceedings of ASCO vol. 1997:37a.
16. Deng JS, Brod BA, Saito R, Tharp MD Immune associated cells in basal cell carcinomas of skin. J Cutaneous Pathol 1996;23:140-146.
17. Deng JS, Falo LD Jr., Kim B, Abell E. Cytotoxic T cells in basal cell carcinoma of skin. Am J Dermatopathol 1998;20:143-146.
18. Czarnecki D, Mar A, Kulinskaya E. Cell mediated immunity of patients who have had basal cell carcinomas. Acto Dermato-Venerolog 1996;76:28-30.
19. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Int Med 1998;129:559-566.
20. Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V. Incidence of post transplant malignancy among 674 solid-organ transplant recipients at a single center. Clin Transplantation 1996;10:248-255.
21. Coso D, Costello R, Cohen-Valensi R, Nezri M, Gastaut JA & Bouaddullah R. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy. Ann Oncol 1999;10:362-363.
22. Frewin RJ, Provan D, Smith AG. Myelodysplasia occurring after fludarabine treatment for chronic lymphocytic leukemia. Clin Lab Ham 1997;19:151-152.
23. Robertson LE, Estey E, Kantarjian H, Koller C, O'Brien S. Brown B, Keating MJ. Therapy related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia 1994;8:2047-2051.
24. Sheilds DJ, Byrd JC, Abbondanzo SL, et al. Detection of EBV in transformation of low grade B cell lymphomas treatment. Md Pathol 1997;10:1551-1559.
25. Palmera L, Azaceta G, Varo MJ, Soria J, Gutierrez M. Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma (letter). Hematologica 1998;83: 10045-10046.
26. Larsen CR, Hansen PB, Clausen NT. Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues. Am J Hematol 2002;70:48-50.